Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Arcus Biosciences (RCUS) stocks in Canada

Learn how to easily invest in Arcus Biosciences stocks.

Arcus Biosciences (RCUS) is a leading biotechnology business based in the US. It opened the day at $28.72 after a previous close of $28.75. During the day the price has varied from a low of $28.46 to a high of $29.185. The latest price was $29.07 (25 minute delay). Arcus Biosciences is listed on the NYSE and employs 500 staff. All prices are listed in US Dollars.

How to buy Arcus Biosciences stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – RCUS. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for Beginners

CIBC Investor's Edge

  • Easy to use platform
  • Low fees
  • Student and young investor discounts

Best for Lowest Commissions

Finder Award

Interactive Brokers

  • Access to international stock exchanges
  • Low margin rates
  • Powerful research tools

Promoted for Free Trades

National Bank Direct Brokerage

  • Commission-free trading
  • Several account types available
  • Access to array of research tools

Arcus Biosciences stock price (NYSE:RCUS)

Use our graph to track the performance of RCUS stocks over time.

Arcus Biosciences shares at a glance

Information last updated 2021-07-09.
Previous close$28.75
Change $0.32
Change % 1.113%
Volume 721,166
Information last updated 2023-03-23.
52-week range$15.70 - $39.75
50-day moving average $19.34
200-day moving average $24.52
Wall St. target price$43.25
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-3.66

Buy Arcus Biosciences stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Available Asset Types Stock Trading Fee Account Fee Table description Signup Offer Offer
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$0 if conditions met, or $100
An easy-to-use platform with access to a variety of tools to help you trade with confidence.
Get 100 free online stock or ETo 24F trades and up to $3,000 cash back. Conditions apply.
Get 100 free online stock or ETF trades and up to $3,000 cash back. Conditions apply.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
min $1.00, max 0.5%
Winner for Best Overall Broker in the Finder Stock Trading Platform Awards.
National Bank Direct Brokerage
Stocks, Bonds, Options, Mutual Funds, GICs
$0 if conditions met, or $100
Get $0 commission on all transactions with promo code: finder
Get $0 commission on all transactions with promo code: finder
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95 - $9.95
Opt for self-directed investing and save on fees or get a pre-built portfolio to take out some of the guesswork.
Get $50 in free trades when you fund your account with a minimum of $1,000.
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options.
Get up to $150 sign-up bonus. Use promo code BONUS150. Conditions apply. Ends June 30, 2023.
Get up to $150 sign-up bonus. Use promo code BONUS150. Conditions apply. Ends June 30, 2023.

Is it a good time to buy Arcus Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Arcus Biosciences price performance over time

Historical closes compared with the close of $29.07 from 2023-03-24

1 week (2023-03-21) 73.76%
1 month (2023-02-28) 59.64%
3 months (2022-12-28) 47.56%
6 months (2022-09-28) 8.47%
1 year (2022-03-24) -16.27%
2 years (2021-03-26) -11.13%
3 years (2020-03-27) 129.44%
5 years (2018-03-28) 81.46%
[/expander_content] [/expander]

Arcus Biosciences financials

Revenue TTM $112 million
Gross profit TTM $-176,000,000
Return on assets TTM -11.92%
Return on equity TTM -35.62%
Profit margin -238.39%
Book value $9.01
Market capitalisation $1.2 billion

TTM: trailing 12 months

Arcus Biosciences share dividends

We're not expecting Arcus Biosciences to pay a dividend over the next 12 months.

Arcus Biosciences share price volatility

Over the last 12 months, Arcus Biosciences's shares have ranged in value from as little as $15.7 up to $39.75. A popular way to gauge a stock's volatility is its "beta".

RCUS.US volatility(beta: 0.88)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Arcus Biosciences's is 0.8819. This would suggest that Arcus Biosciences's shares are less volatile than average (for this exchange).

Arcus Biosciences overview

Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L. P.

Stocks similar to Arcus Biosciences

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site